
Diego A. Díaz García/X
Apr 2, 2025, 10:53
Diego A. Díaz García: Cross-priming is key in cancer immunotherapy
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared an article by Carlos Luri-Rey, et al. on X:
“Cross-priming is key in cancer immunotherapy.
- cDC1s cross-present tumor antigens & activate CD8+ T cells.
- Their abundance correlates with ICI response.
- FLT3L-based therapies show promise in trials.”
Cross-priming in cancer immunology and immunotherapy.
Authors: Carlos Luri-Rey, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 2, 2025, 11:56
Apr 2, 2025, 10:53
Apr 2, 2025, 10:05